New Approaches to Dementia Heterogeneity

痴呆症异质性的新方法

• 批准号: 9922212
• 负责人: BRUCE L MILLER
• 金额: $ 315.84万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9922212
• 关键词: Aging; Alzheimer' s Disease; American; Award; Basic Science; Biological; Biological Markers; Biology; Biometry; Caregiver support; Caring; Chinese People; Clinical; Clinical Data; Clinical Paths; Clinical Trials; Cognition Disorders; Collaborations; Collection; Communities; Creutzfeldt-Jakob Syndrome; Data; Dementia; Diagnosis; Diagnostic; Disease; Education; Evaluation; Film; Foundations; Frontotemporal Dementia; Funding; Gender; Generations; Genetic; Genomics; Grant; Heterogeneity; Image; Industry Collaboration; Institutes; International; K-Series Research Career Programs; Knowledge; Latino; Lead; Leadership; Medical; Medical Genetics; Memory; Minority; Modeling; Molecular; Neurodegenerative Disorders; Neurologic; Neurologist; Neurosciences; Nurses; Online Systems; Pathologic; Pathology; Performance; Physiological; Policies; Population Heterogeneity; Presenile Alzheimer Dementia; Process; Progressive Supranuclear Palsy; Proteomics; Public Health; Research; Research Personnel; Resources; Sampling; Science; Scientist; Site; Specialist; Specialized Center; Tablets; Talents; Tauopathies; Training; United States National Institutes of Health; Work; base; brain health; career; catalyst; clinical center; clinical diagnostics; clinical phenotype; cohort; community center; corticobasal syndrome; data management; data sharing; drug development; education research; ethnic diversity; health care delivery; health economics; health equity; healthy aging; imaging biomarker; improved; innovation; lectures; normal aging; novel; novel strategies; outreach; programs; ranpirnase; recruit; statistics; symposium; tau Proteins; therapy development; transcriptomics; translational scientist

ABSTRACT The UCSF Alzheimer’s Disease Research Center (ADRC) is a major catalyst for a broad spectrum of dementia-related research conducted at UCSF and has served as a cornerstone for national and international multi-site diagnostic and treatment studies. In three previous cycles of funding under the P50 mechanism, we have organized a critical mass of dementia research and share our resources widely. We excel in clinical phenotyping, imaging, biospecimen collection, and pathologic evaluation of large and unique cohorts of early- onset AD (EOAD), frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), Creutzfeldt-Jakob disease (CJD), and healthy controls. The ADRC supports and effectively leverages additional NIH and foundation funding, philanthropy, and industry collaborations to accomplish its aims. At the UCSF Memory and Aging Center alone, ADRC clinical cohorts, data, and biosamples are currently utilized by 26 R grants, 6 K awards, 4 U grants, and 38 non-NIH grants. Projects and pilot awards have helped launch young investigator careers and major research programs. ADRC data and biosamples are utilized extensively by other ADRCs and an extensive network of collaborators. In this new P30 application, we accelerate efforts to define subtypes of healthy aging, MCI, AD, FTD, PSP, CBS, and CJD that predict specific molecular and physiological causes for dementia, improve early recognition and tracking of transitions from normal aging to dementia, and stimulate drug development and clinical trials. The ADRC will consist of seven cores: Administrative, Clinical, Data Management and Statistics, Pathology, Outreach Recruitment and Engagement, Imaging, and Biomarker and a Research Education Component. These cores will work collectively to pursue the following overarching specific aims: Aim 1: Explore the heterogeneous features of healthy aging, MCI, AD, FTD-spectrum disorders, and CJD to better understand their clinical, genetic, and molecular underpinnings. Aim 2: Leverage the valuable cohorts in the ADRC and the talented neuroscience communities at UCSF and beyond to “enhance the performance of innovative research” around diagnosis and treatment of dementia. Aim 3: Increase understanding of the unique cultural and biological features of aging Chinese and Latino Americans, while educating these communities with outreach lectures and web-based presentations. Aim 4: Develop innovative approaches to data management and biostatistics to support easy access and analysis of ADRC-related data while offering statistical support to our investigators. Aim 5: Train new leaders in dementia research with innovative education approaches and educate medical and lay communities about the heterogeneity of dementia with conferences, web-based presentations, and films. Aim 6: Create a new Biomarker Core to enhance the genomic, proteomic, and transcriptomic data captured from our extensive biospecimen collection. Aim 7: Transition to a more gender and ethnically diverse ADRC leadership by 2024.

摘要 加州大学旧金山分校阿尔茨海默病研究中心（ADRC）是一个主要的催化剂，为广泛的 痴呆症相关的研究在加州大学旧金山分校进行，并已成为国家和国际的基石 多中心诊断和治疗研究。在P50机制下的前三个供资周期中，我们 组织了大量的痴呆症研究，并广泛分享我们的资源。我们擅长临床 表型分析、成像、生物标本采集和病理学评价， 发作性AD（EOAD）、额颞叶痴呆（FTD）、进行性核上性麻痹（PSP）、皮质基底动脉 综合征（CBS）、克雅氏病（CJD）和健康对照。ADRC支持并有效地 利用额外的NIH和基金会资金，慈善事业和行业合作，以实现其 目标。仅在UCSF记忆和衰老中心，ADRC临床队列，数据和生物样本目前正在进行研究。 由26个R赠款，6个K补助金，4个U赠款和38个非NIH赠款使用。项目和试点奖励有助于 启动青年研究员职业和重大研究项目。利用ADRC数据和生物样品 其他ADRC和广泛的合作者网络进行了广泛的研究。 在这个新的P30应用程序中，我们加快了定义健康老龄化，MCI，AD，FTD，PSP， CBS和CJD预测痴呆症的特定分子和生理原因， 跟踪从正常衰老到痴呆症的转变，并刺激药物开发和临床试验。 ADRC将由七个核心组成：行政、临床、数据管理和统计、病理学， 外展招募和参与，成像，生物标志物和研究教育组成部分。这些 核心将共同努力实现以下总体目标：目标1：探索异构 健康老龄化，MCI，AD，FTD谱系障碍和CJD的特征，以更好地了解他们的临床，遗传， 和分子基础。目标2：利用ADRC中有价值的队列和有才华的神经科学 社区在加州大学旧金山分校和超越“提高创新研究的表现”周围的诊断和 治疗痴呆症。目标3：增加对老龄化独特的文化和生物特征的了解 中国人和拉丁美洲人，同时通过外展讲座和基于网络的教育这些社区， 介绍。目标4：开发创新的数据管理和生物统计方法， 访问和分析ADRC相关数据，同时为我们的研究人员提供统计支持。目标5：培训 痴呆症研究的新领导者，采用创新的教育方法， 社区关于痴呆症的异质性与会议，基于网络的演示，和电影。 目标6：创建一个新的生物标志物核心，以增强从生物标志物中捕获的基因组、蛋白质组和转录组数据。 我们大量的生物样本目标7：过渡到性别和族裔更加多样化的亚洲减灾中心 到2024年的领导力。